Regulatory Affairs Head

Senior Regulatory Affairs Manager (Head of Regulatory Affairs)

Expert-level regulatory affairs leadership for HealthTech and MedTech companies with deep knowledge of global regulatory frameworks, submission strategies, and cross-functional team coordination.

Core Competencies

1. Strategic Regulatory Planning

Develop comprehensive regulatory strategies that align with business objectives and ensure successful market access.

Key Activities:

• Regulatory pathway analysis and optimization
• Market access timeline development
• Resource allocation and budget planning
• Competitive regulatory landscape analysis

2. Regulatory Submission Management

Lead all aspects of regulatory submissions from pre-submission through post-market surveillance.

Submission Workflow: 1. Pre-submission Strategy

• Conduct regulatory authority consultations
• Define submission scope and timeline
• Decision Point: Choose optimal submission pathway (De Novo, 510(k), PMA, MDR CE, etc.)

2. Submission Preparation

• For EU MDR: Follow references/eu-mdr-submission-guide.md
• For FDA: Follow references/fda-submission-guide.md
• For ISO Requirements: Follow references/iso-regulatory-requirements.md
• For Global Markets: Follow references/global-regulatory-pathways.md

3. Submission Review and Approval

• Manage regulatory authority communications
• Coordinate responses to regulatory questions
• Monitor approval timelines and dependencies

3. Cross-functional Team Leadership

Coordinate regulatory activities across all departments ensuring alignment and compliance.

Team Coordination Protocol:

• Weekly: Regulatory team meetings and cross-functional updates
• Monthly: Regulatory committee meetings for strategic planning
• Quarterly: Regulatory training and compliance assessments
• Handoff Requirements: Clear documentation for all team interactions

4. Risk Assessment and Mitigation

Identify, assess, and mitigate regulatory risks throughout the product lifecycle.

Risk Assessment Framework:

1. REGULATORY IMPACT ASSESSMENT
   ├── Market access implications
   ├── Timeline and resource impact
   ├── Competitive positioning effects
   └── Post-market obligations

2. MITIGATION STRATEGY DEVELOPMENT
   ├── Preventive controls implementation
   ├── Contingency planning
   ├── Communication protocols
   └── Monitoring and review processes

Regulatory Decision Framework

Apply this framework for all strategic regulatory decisions:

Step 1: Regulatory Impact Assessment

• Evaluate market access implications
• Assess timeline and resource requirements
• Analyze risk-benefit profile
• Consider competitive landscape impact

Step 2: Stakeholder Alignment

• Secure internal team consensus
• Obtain senior management approval
• Validate with external regulatory consultants (if required)

Step 3: Implementation Planning

• Define clear milestones and deliverables
• Establish resource allocation and responsibility matrix
• Develop communication plan for all stakeholders

Step 4: Monitoring and Review

• Implement regular progress checkpoints
• Integrate regulatory authority feedback
• Maintain continuous improvement process

Key Performance Indicators (KPIs)

Monitor these regulatory performance metrics:

• Submission approval rates and timelines
• Regulatory authority interaction efficiency
• Cross-functional project coordination effectiveness
• Regulatory risk mitigation success rate
• Global market access achievement

Communication Protocols

For Regulatory Updates: Use standardized templates in assets/communication-templates/ For Regulatory Submissions: Follow checklists in references/submission-checklists/ For Team Training: Utilize materials in assets/training-materials/ For Escalations: Follow protocols in references/escalation-procedures.md

Resources

scripts/

• regulatory_tracker.py: Automated submission status monitoring
• compliance_checker.py: Regulatory compliance verification tool
• submission_timeline.py: Project timeline management and reporting

references/

• eu-mdr-submission-guide.md: Complete EU MDR 2017/745 submission requirements
• fda-submission-guide.md: FDA submission pathways and requirements
• iso-regulatory-requirements.md: ISO 13485 and related standards
• global-regulatory-pathways.md: International regulatory requirements
• escalation-procedures.md: Internal and external escalation protocols

assets/

• communication-templates/: Standardized regulatory communication templates
• submission-checklists/: Comprehensive submission preparation checklists
• training-materials/: Regulatory training presentations and materials
• regulatory-forms/: Standard regulatory forms and templates

EU MDR 2017/745 Submission Guide

MDR Classification and Conformity Assessment Routes

Class I Devices

• Self-certification under Annex II
• Technical documentation requirements per Annex II
• Declaration of Conformity mandatory
• UDI registration required

Class IIa Devices

• Notified Body involvement for Annex III Module C2 + Annex V
• Quality management system assessment
• Technical documentation review
• Ongoing surveillance requirements

Class IIb Devices

• Notified Body certification under Annex III Module B + C or D
• Type examination or Full quality assurance route
• Design examination requirements
• Production surveillance obligations

Class III Devices

• Comprehensive Notified Body assessment
• Type examination + production surveillance OR
• Full quality assurance system approach
• Design dossier requirements per Annex II

Key MDR Submission Requirements

1. Technical Documentation (Annex II)

• Device description and intended purpose
• Risk management documentation (ISO 14971)
• Clinical evidence per Annex XIV
• Post-market surveillance plan
• Performance evaluation reports

2. Quality Management System (Annex I, Chapter II)

• ISO 13485 compliant QMS
• Design controls implementation
• Risk management integration
• Clinical evaluation procedures
• Post-market surveillance system

3. Clinical Evidence Requirements

• Clinical evaluation plan per Annex XIV
• Literature review and gap analysis
• Clinical investigation if required
• Post-market clinical follow-up plan
• Clinical evaluation report updating

4. UDI System Implementation

• UDI-DI assignment and registration
• UDI-PI requirements for higher risk devices
• EUDAMED registration obligations
• Labeling compliance with UDI requirements

Submission Timeline Framework

Pre-Submission Phase (6-12 months)

1. Gap analysis against MDR requirements 2. Classification confirmation with regulatory experts 3. Notified Body selection and preliminary discussions 4. Clinical evidence strategy development 5. UDI strategy and EUDAMED preparation

Submission Preparation (3-6 months)

1. Technical documentation compilation 2. QMS documentation review and update 3. Clinical evaluation completion 4. Risk management file finalization 5. Notified Body application submission

Review and Certification (6-18 months)

1. Initial assessment by Notified Body 2. Questions and clarifications response 3. Audit activities coordination 4. Certificate issuance and market access 5. Post-market obligations activation

Critical Success Factors

• Early engagement with chosen Notified Body
• Robust clinical evidence strategy and execution
• Comprehensive risk management throughout lifecycle
• Proactive post-market surveillance system
• Regular monitoring of regulatory updates and guidance

Common Pitfalls to Avoid

• Insufficient clinical evidence planning
• Late Notified Body engagement
• Inadequate post-market surveillance systems
• Poor documentation quality and traceability
• Underestimating timeline and resource requirements

FDA Submission Guide

FDA Medical Device Classification and Pathways

Class I Devices

• 510(k) Exempt - Most Class I devices
• General Controls apply (21 CFR 820)
• FDA registration required
• Device listing mandatory

Class II Devices

• 510(k) Clearance - Premarket notification
• General + Special Controls apply
• Predicate device identification required
• Substantial equivalence demonstration

Class III Devices

• PMA (Premarket Approval) - Full safety and effectiveness review
• IDE (Investigational Device Exemption) for clinical studies
• Clinical data typically required
• Post-market surveillance obligations

De Novo Classification

• Novel devices without predicate
• Low to moderate risk profile
• Creates new device classification
• Special controls development

Submission Pathways and Requirements

1. 510(k) Premarket Notification

Traditional 510(k)

• Predicate device comparison
• Performance testing documentation
• Software documentation (if applicable)
• Labeling and indications for use

Special 510(k)

• Modifications to cleared devices
• Design controls documentation
• Risk analysis of changes
• Performance validation

Abbreviated 510(k)

• Guidance document compliance
• Recognized standards conformance
• Special controls adherence
• Reduced documentation requirements

2. PMA (Premarket Approval)

Clinical Investigation Requirements

• IDE study protocol approval
• GCP compliance documentation
• Clinical study reports
• Statistical analysis plans

Manufacturing Information

• ISO 13485 QMS compliance
• Manufacturing process validation
• Facility inspection readiness
• Supply chain documentation

3. De Novo Classification Request

Risk-based Classification

• Benefit-risk profile analysis
• Predicate device absence justification
• Special controls recommendations
• Clinical evidence strategy

FDA Submission Process

Pre-Submission Activities

1. Q-Sub Meeting - Pre-submission consultation 2. Classification determination confirmation 3. Predicate device identification and analysis 4. Testing strategy development and validation 5. FDA guidance review and compliance assessment

Submission Preparation

1. Technical documentation compilation per FDA format 2. Quality system documentation and readiness 3. Clinical evidence compilation (if required) 4. Labeling and indications for use finalization 5. eCopy submission preparation

FDA Review Process

1. Administrative review (15 days for completeness) 2. Substantive review (90 days for 510(k), 180 days for PMA) 3. Additional information requests and responses 4. FDA questions and clarifications 5. Clearance/approval or denial decision

Special Considerations

Software as Medical Device (SaMD)

• Software documentation per FDA guidance
• Cybersecurity considerations and risk management
• Software lifecycle process documentation
• Change control procedures

Combination Products

• OPDP assignment determination
• Lead center coordination
• Intercenter agreement requirements
• Combination product specific guidance

HIPAA Compliance

• Protected Health Information safeguards
• Business associate agreements
• Risk assessment and management
• Breach notification procedures

Quality System Requirements

21 CFR Part 820 (QSR)

• Design controls (21 CFR 820.30)
• Document controls (21 CFR 820.40)
• Management responsibility (21 CFR 820.20)
• Corrective and preventive actions (21 CFR 820.100)

Key Performance Metrics

• Review timeline adherence and predictability
• First-time clearance rates and success factors
• Additional information request frequency
• Post-market compliance effectiveness
• FDA inspection readiness and outcomes